Video

USP Survey Shows 9 Out of 10 Physicians Feel Their Trust in Medicine Supply Chain Has Eroded

Ronald T. Piervincenzi, CEO of US Pharmacopeia (USP), discusses recent survey data demonstrating 90% of physicians had experienced an erosion of trust in the US supply chain’s ability to deliver safe, quality medicines.

Pharmacy Times interviewed Ronald T. Piervincenzi, CEO of US Pharmacopeia (USP), on a recent USP survey that showed 9 out of 10 physicians feel their trust in the ability of the US supply chain to deliver safe, quality medicines has eroded.

During the interview, Piervincenzi addressed what this survey has brought to light in terms of the pandemic’s impact on health care professionals’ perception of the medicine supply chain, where this perception among health care professionals may have come from, and whether their lack of trust in the medicine supply chain is well-founded.

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC